Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sorafenib as Inhibitor of Collateral Tumor Vessel Growth During Transarterial Chemoembolisation (TACE) for Hepatocellular Carcinoma (HCC)- a Pilot Trial to Evaluate Safety and Biological Response

Next Previous
Trial Profile

Sorafenib as Inhibitor of Collateral Tumor Vessel Growth During Transarterial Chemoembolisation (TACE) for Hepatocellular Carcinoma (HCC)- a Pilot Trial to Evaluate Safety and Biological Response

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sorafenib (Primary) ; Doxorubicin; Ethiodized oil
  • Indications Liver cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Soratace-1

Most Recent Events

  • 15 Mar 2012 Actual end date changed from Nov 2010 to Mar 2011 as reported by European Clinical Trials Database.
  • 15 Mar 2012 Actual initiation date changed from Sep 2008 to Mar 2008 as reported by European Clinical Trials Database.
  • 08 Nov 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top